Depression in Parkinson disease: Current understanding and treatment

International Journal of Gerontology

Volumn 2, Issue 4, 2008, Pages 172-182

  Chen, Pei Hao ^a   Cheng, Shih Jung ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antidepressive agents; Anxiety; Neurogenic urinary bladder; Psychotic disorders; Sleep disorders

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DOXEPIN; ENTACAPONE; FLUOXETINE; IMIPRAMINE; LEVODOPA; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OXYBUTYNIN; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM;

AGED; AGITATION; ANTICHOLINERGIC SYNDROME; ANXIETY; BEHAVIOR DISORDER; BLADDER DYSFUNCTION; BODY WEIGHT; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSKINESIA; DYSTONIA; HALLUCINATION; HEART DISEASE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SCREENING; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYMPTOM; TACHYCARDIA; TREMOR; VASCULAR DISEASE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 59149086185     PISSN: 18739598     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1873-9598(09)70006-7     Document Type: Review

References (90)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-93.
2. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-9.
3. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005; 76 (Suppl 1): i48-52.
4. Pålhagen SE, Carlsson M, Curman E, Wålinder J, Granérus AK. Depressive illness in Parkinson's disease - indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 2008; 117: 295-304.
5. Carod-Artal FJ, Vargas AP, Martinez-Martin P. Determinants of quality of life in Brazilian patients with Parkinson's disease. Mov Disord 2007; 22: 1408-15.
6. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16: 178-83.
7. Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th edition. Text revised. Washington, DC: American Psychiatric Association Press, 2000.
8. Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry 1999; 7: 110-8.
9. Richard IH. Apathy does not equal depression in Parkinson disease: why we should care. Neurology 2006; 67: 10-1.
10. Hoogendijk WJ, Sommer IE, Tissingh G, Deeg DJ, Wolters EC. Depression in Parkinson's disease: the impact of symptom overlap on prevalence. Psychosomatics 1998; 39: 416-21.
11. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-58.
12. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363-75.
13. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-92.
14. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17: 445-54.
15. Leentjens AF. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17: 120-6.
16. Lieberman AN. Depression in Parkinson's disease. Barrow Neurol Inst Quart 1997; 3: 27-33.
17. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006; 113: 211-20.
18. Mann JJ, Kapur S. A dopaminergic hypothesis of major depression. Clin Neuropharmacol 1995; 18: S57-65.
19. Okun MS, Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology 2002; 58 (4 Suppl 1): S63-70.
20. Berg D, Supprian T, Hofmann E, Zeiler B, Jager A, Lange KW, et al. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 1999; 246: 1186-93.
21. Borek LL, Chou KL, Friedman JH. Management of the behavioral aspects of Parkinson's disease. Expert Rev Neurother 2007; 7: 711-25.
22. Brooks DJ, Piccini P. imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry 2006; 59: 908-18.
23. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61-84.
24. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008; 23: 631-40.
25. Nissinen E, Nissinen H, Larjonmaa H, Väänänen A, Helkamaa T, Reenilä I, et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 2005; 112: 1213-21.
26. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-8.
27. Müller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006; 62: 447-50.
28. Valkovic P, Benetin J, Blazícek P, Valkovicová L, Gmitterová K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11: 253-6.
29. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 1999; 19: 329-35.
30. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
31. Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep 2007; 59: 778-84.
32. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007; 68: 1230-6.
33. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
34. Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50: 357-60.
35. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
36. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; 1: CD003491.
37. Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol 2008; 15: 21-5.
38. Kingsbury SJ, Simpson GM. Considerations in choosing an antidepressant. Psychiatr Serv 2001; 52: 1435-6.
39. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997; 49: 1168-70.
40. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999; 14: 155-7.
41. Arbouw ME, Movig KL, Neef C, Guchelaar HJ, Egberts TC. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol 2007; 63: 181-7.
42. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002; 25: 21-4.
43. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 (11 Suppl 5): S1-88.
44. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984; 34: 1092-4.
45. Grandas F, López-Manzanares L. Bupropion-induced parkinsonism. Mov Disord 2007; 22: 1830-1.
46. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999; 53: 1154.
47. Onofrj M, Luciano AL, Thomas A, Iacono D, D'Andreamatteo G. Mirtazapine induces REM sleep behavior disorder (RBD) in Parkinsonism. Neurology 2003; 160: 113-5.
48. Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406.
49. Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology 2003; 61: S17-23.
50. Comella CL. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003; 3: 173-80.
51. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005; 28: 298-301.
52. Korczyn AD. Management of sleep problems in Parkinson's disease. J Neurol Sci 2006; 248: 163-6.
53. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinson's disease. Neurourol Urodyn 2006; 25: 116-22.
54. Barrero R, Mir P, Cayuela A, Campoy P, Pena JM, Alberca R. [Urinary symptoms and urodynamic findings in Parkinson's disease.] Neurologia 2007; 22: 93-8. [In Spanish]
55. Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic nervous system dysfunction in Parkinson's disease. Curr Treat Options Neurol 2003; 5: 149-60.
56. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5.
57. Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000; 79: 191-5.
58. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21: 737-45.
59. Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry 2003; 54: 262-8.
60. Antai-Otong D. The art of prescribing. Antidepressants in late-life depression: prescribing principles. Perspect Psychiatr Care 2006; 42: 149-53.
61. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44.
62. Silva EG, Viana MA, Quagliato EM. Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. Arq Neuropsiquiatr 2008; 66: 26-9.
63. Waseem S, Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001; 110: 33-40, 46.
64. Sage JI. Pain in Parkinson's Disease. Curr Treat Options Neurol 2004; 6: 191-200.
65. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005; 20: 1557-63.
66. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005; 71: 483-90.
67. Reeves RR, Cox SK. Similar effects of tramadol and venlafaxine in major depressive disorder. South Med J 2008; 101: 193-5.
68. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 383-92.
69. Lieberman A. Depression in Parkinson's disease: a review. Acta Neurol Scand 2006; 113: 1-8.
70. Sawabini KA, Watts RL. Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord 2004; 10: S37-41.
71. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001; 77: 89-93.
72. Barbas NR. Cognitive, affective, and psychiatric features of Parkinson's disease. Clin Geriatr Med 2006; 22: 773-96.
73. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin 2008; 24: 157-66.
74. Weintraub D, Comella CL, Horn S. Parkinson's disease - Part 3: Neuropsychiatric symptoms. Am J Manag Care 2008; 14 (2 Suppl): S59-69.
75. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez-Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 2008; 65: 414-9.
76. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007; 17: 165-71.
77. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 1995; 95: 979-83.
78. Kashihara K. Weight loss in Parkinson's disease. J Neurol 2006; 253 (Suppl 7): VII38-41.
79. Pålhagen S, Lorefält B, Carlsson M, Ganowiak W, Toss G, Unosson M, et al. Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? Acta Neurol Scand 2005; 111: 12-20.
80. Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E. Increase in body weight after pramipexole treatment in Parkinson's disease. Mov Disord 2006; 21: 1972-4.
81. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson's disease. Mov Disord 2006; 21: 1824-30.
82. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220.
83. Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev 2004; 5: 167-70.
84. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842-7.
85. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61: 37-41.
86. Driscoll HC, Karp JF, Dew MA, Reynolds CF 3rd. Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age. Drugs Aging 2007; 24: 801-14.
87. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008; 63: 699-704.
88. Richard IH. Depression in Parkinson's disease. Curr Treat Options Neurol 2000; 2: 263-73.
89. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005; 17: 310-23.
90. Fregni F, Pascual-Leone A. Transcranial magnetic stimulation for the treatment of depression in neurologic disorders. Curr Psychiatry Rep 2005; 7: 381-90.